Since KemPharm Inc. (NASDAQ:KMPH) and Cellular Biomedicine Group Inc. (NASDAQ:CBMG) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation of both companies.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KemPharm Inc.	N/A	0.00	61.85M	-4.09	0.00
Cellular Biomedicine Group Inc.	N/A	1208.11	37.35M	-3.34	0.00

Table 1 shows the gross revenue, earnings per share and valuation for KemPharm Inc. and Cellular Biomedicine Group Inc.

Profitability

Table 2 represents KemPharm Inc. (NASDAQ:KMPH) and Cellular Biomedicine Group Inc. (NASDAQ:CBMG)’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
KemPharm Inc.	0.00%	78.3%	-167.3%
Cellular Biomedicine Group Inc.	0.00%	-48.3%	-45.3%

Volatility & Risk

KemPharm Inc. is 24.00% less volatile than Standard & Poor’s 500 due to its 0.76 beta. In other hand, Cellular Biomedicine Group Inc. has beta of 3.71 which is 271.00% more volatile than Standard & Poor’s 500.

Liquidity

KemPharm Inc.’s Current Ratio is 0.9 while its Quick Ratio is 0.9. On the competitive side is, Cellular Biomedicine Group Inc. which has a 11.9 Current Ratio and a 11.9 Quick Ratio. Cellular Biomedicine Group Inc. is better positioned to pay off short and long-term obligations compared to KemPharm Inc.

Analyst Recommendations

KemPharm Inc. and Cellular Biomedicine Group Inc. Ratings and Recommendations are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
KemPharm Inc.	0	0	0	0.00
Cellular Biomedicine Group Inc.	0	0	2	3.00

Competitively Cellular Biomedicine Group Inc. has a consensus price target of $32, with potential upside of 82.23%.

Insider and Institutional Ownership

KemPharm Inc. and Cellular Biomedicine Group Inc. has shares held by institutional investors as follows: 19.6% and 18.3%. About 6.9% of KemPharm Inc.’s share are held by insiders. Competitively, 38.95% are Cellular Biomedicine Group Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
KemPharm Inc.	5.08%	3.07%	-48.52%	-61.29%	-26.3%	-33.58%
Cellular Biomedicine Group Inc.	-6.92%	8.54%	-14.71%	2.77%	71.76%	64.89%

For the past year KemPharm Inc. has -33.58% weaker performance while Cellular Biomedicine Group Inc. has 64.89% stronger performance.

Summary

Cellular Biomedicine Group Inc. beats KemPharm Inc. on 7 of the 8 factors.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. The company is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. KemPharm, Inc. was founded in 2006 and is headquartered in Coralville, Iowa.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy. The company has a strategic research collaboration with GE Healthcare Life Sciences China to co-develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing. Cellular Biomedicine Group Inc. was incorporated in 2001 and is headquartered in Cupertino, California.